Raiffeisen Investment
Print Page   Close

Life Sciences

The rising purchasing power of the population is also one of the reasons why the Eastern European Life Science market has been experiencing double-digit growth rates within the last years. Western as well as large Eastern European pharma players and an ever growing number of private equity funds are looking at the remaining generics companies in Eastern Europe.

Our sector knowledge together with the indispensable know how of the local culture, relationships and industries provided by our subsidiaries in every major CEE capital enable us to provide our clients with everything that is needed to realize their M&A ambitions in Central and Eastern Europe.

Contact

Klaus Imhof, Director


Raiffeisen Investment AG
Krugerstraße 13
1015 Vienna
AUSTRIA

People

Photo: Klaus ImhofKlaus Imhof

Tel: +43 1 710 54 00 147

Fax: +43 1 710 54 00 139

e-mail

Latest Credentials

  • recordatinewIn 2011 Raiffeisen Investment advised Recordati, an European pharmaceutical group...

    In 2009 Raiffeisen Investment advised BC Partners on the acquisition of the Central European medical laboratory group FutureLab  ...

  • medlifeIn 2009 Société Générale Asset Management acquired a minority stake in MedLife SA, the largest private healthcare operator in Romania ...
  • Yeni-IlacIn 2008 Recordati Group acquired a 100 % stake in the share capital of Turkish Yeni Ilac ....
  • labormedIn 2008, Raiffeisen Investment Romania acted as the sell-side M&A advisor  ...
  •  

  • akrihinIn March 2007, Raiffeisen Investment acted as sell-side advisor to VIP Progress (Overseas) ...
  • In July 2006, Andreas Noris Zahn AG (ANZAG) acquired 60% of the sharecapital of ...

All sector credentialsAll credentials